

Giacomo Zaccherini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3937185/publications.pdf>

Version: 2024-02-01

63
papers

6,684
citations

257450

24
h-index

161849

54
g-index

64
all docs

64
docs citations

64
times ranked

4979
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1426-1437.e9.	1.3	2,211
2	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	3.7	741
3	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	7.3	550
4	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252.	7.3	493
5	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	13.7	345
6	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	1.3	296
7	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	3.7	289
8	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	3.7	282
9	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223
10	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	3.7	149
11	QT interval prolongation in liver cirrhosis: innocent bystander or serious threat?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 57-66.	3.0	86
12	Role of Human Albumin in the Management of Complications of Liver Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 302-311.	0.9	84
13	Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment. <i>JHEP Reports</i> , 2021, 3, 100176.	4.9	84
14	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.	3.7	76
15	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	8.1	75
16	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	7.3	67
17	Human albumin in the management of complications of liver cirrhosis. <i>Critical Care</i> , 2012, 16, 211.	5.8	63
18	Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. <i>Atherosclerosis</i> , 2010, 208, 222-227.	0.8	61

#	ARTICLE	IF	CITATIONS
19	Mortality rate and risk factors for gastrointestinal bleeding in elderly patients. <i>European Journal of Internal Medicine</i> , 2019, 61, 54-61.	2.2	52
20	Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl4-induced advanced cirrhosis. <i>Laboratory Investigation</i> , 2012, 92, 384-395.	3.7	51
21	Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. <i>Internal and Emergency Medicine</i> , 2018, 13, 1191-1200.	2.0	45
22	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. <i>Journal of Hepatology</i> , 2021, 74, 1117-1131.	3.7	45
23	Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. <i>Hepatology</i> , 2021, 74, 2058-2073.	7.3	45
24	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	3.7	38
25	How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. <i>World Journal of Gastroenterology</i> , 2011, 17, 3479.	3.3	26
26	Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. <i>Drugs and Aging</i> , 2018, 35, 365-373.	2.7	17
27	The Analysis of Food Intake in Patients with Cirrhosis Waiting for Liver Transplantation: A Neglected Step in the Nutritional Assessment. <i>Nutrients</i> , 2019, 11, 2462.	4.1	16
28	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	3.7	16
29	Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature. <i>Hepatic Medicine: Evidence and Research</i> , 2020, Volume 12, 153-172.	2.5	15
30	Approach and management of dysnatremias in cirrhosis. <i>Hepatology International</i> , 2018, 12, 487-499.	4.2	14
31	Management of Ascites in Patients with Cirrhosis: An Update. <i>Journal of Clinical Medicine</i> , 2021, 10, 5226.	2.4	14
32	Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. <i>JHEP Reports</i> , 2019, 1, 270-277.	4.9	12
33	Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (Registro Politerapie Societ� Italiana di Medicina) Tj ETQq1 1 0.784314 ogBT /Over		
34	Pro: The Role of Albumin in Pre-Liver Transplant Management. <i>Liver Transplantation</i> , 2019, 25, 128-134.	2.4	9
35	Albumin: Indications in chronic liver disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 528-535.	3.8	9
36	A Case of Prolonged Cholestatic Hepatitis Induced by Azithromycin in a Young Woman. <i>Case Reports in Hepatology</i> , 2011, 2011, 1-4.	0.7	7

#	ARTICLE	IF	CITATIONS
37	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa453.	0.9	7
38	A web-based group treatment for patients with alcoholic liver diseases at the time of the COVID-19 pandemic. <i>Digestive and Liver Disease</i> , 2020, 52, 956-957.	0.9	7
39	Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease. <i>Current Hepatology Reports</i> , 2020, 19, 147-158.	0.9	7
40	PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. <i>Journal of Hepatology</i> , 2019, 70, e53.	3.7	5
41	Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 1313-1317.e9.	2.5	5
42	OO9â€¦A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients. , 2021, , .		5
43	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112.	4.3	5
44	Low Adherence To Nutritional Recommendations In Patients With Cirrhosis: A Prospective Observational Study. <i>Journal of Gastroenterology and Hepatology Research</i> , 2019, 8, 2896-2902.	0.2	4
45	Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference. <i>Annals of Translational Medicine</i> , 2019, 7, S201-S201.	1.7	4
46	Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. <i>Journal of Clinical Medicine</i> , 2021, 10, 4590.	2.4	4
47	Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study. <i>Digestive and Liver Disease</i> , 2015, 47, e6.	0.9	3
48	A Case of Immuneâ€¦Mediated Liver Injury Induced by Olaparib. <i>Hepatology</i> , 2018, 68, 2039-2041.	7.3	3
49	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. <i>European Journal of Internal Medicine</i> , 2019, 68, e7-e11.	2.2	2
50	Long-term albumin administration in patients with cirrhosis and uncomplicated ascites: the use of serum albumin concentration for personalizing treatment. <i>Digestive and Liver Disease</i> , 2019, 51, e9.	0.9	2
51	Hyposplenism as a cause of pneumococcal meningococcal meningitis in an adult patient with coeliac disease. <i>Italian Journal of Medicine</i> , 2011, 5, 124-127.	0.3	1
52	Bacterial infections with and without acute-on-chronic liver failure in patients with cirrhosis and acute decompensation: Risk factors and outcome. <i>Digestive and Liver Disease</i> , 2018, 50, 10.	0.9	1
53	The residual native albumin predicts albumin dysfunction and outcomes in hospitalized cirrhotic patients with acute decompensation or acute-on-chronic liver failure. <i>Digestive and Liver Disease</i> , 2019, 51, e41.	0.9	1
54	Long-term albumin therapy is not futile in patients with cirrhosis and uncomplicated ascites not normalizing on-treatment serum albumin concentration. <i>Digestive and Liver Disease</i> , 2020, 52, e57-e58.	0.9	1

#	ARTICLE	IF	CITATIONS
55	A case of pneumonia and sepsis in cirrhosis as paradigm of the problems in the management of bacterial infections in cirrhosis and of the limitations of current knowledge. Italian Journal of Medicine, 2013, , 209-214.	0.3	0
56	Outcome of bacterial infections complicated or not by acute-on-chronic liver failure in patients with cirrhosis admitted to hospital for acute decompensation. Journal of Hepatology, 2018, 68, S248.	3.7	0
57	PS-102-Circulating native albumin in patients with cirrhosis admitted to hospital for acute decompensation and acute-on-chronic liver failure: Relation to serum albumin levels, albumin function, and patient outcomes. Journal of Hepatology, 2019, 70, e65.	3.7	0
58	SAT-152-Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. Journal of Hepatology, 2019, 70, e698.	3.7	0
59	Effective albumin concentration and albumin function improve after long-term albumin treatment in patients with decompensated cirrhosis. Journal of Hepatology, 2020, 73, S211-S212.	3.7	0
60	Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment. Journal of Hepatology, 2020, 73, S738.	3.7	0
61	Bacterial infections in patients with liver cirrhosis. Reviews in Health Care, 2011, 2, 147-159.	0.1	0
62	A look at the hepatic encephalopathy in cirrhosis. Reviews in Health Care, 2013, 4, 55-74.	0.1	0
63	The use of albumin in the complications of cirrhosis: evidence and future perspectives. Reviews in Health Care, 2013, 4, 159-173.	0.1	0